Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;148(6):1493-1500.
doi: 10.1007/s00432-021-03749-6. Epub 2021 Jul 28.

Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study

Wan Qianyi  1 , Xu Mei  2 , Zhao Rui  1 , Wang Yong  1 , Wu Yutao  1   2 , Shen Xiaoding  1 , Wu Xiaoting  3
Affiliations

Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study

Wan Qianyi et al. J Cancer Res Clin Oncol. 2022 Jun.

Abstract

Purpose: To investigate the impact of delayed adjuvant imatinib on GIST patients with high risk of recurrence.

Method: Adult GIST patients were retrospectively collected from our hospital between 2011 and 2018, and patients having high risk of recurrence were included for subsequent analyses. The primary endpoint was recurrence-free survival (RFS).

Results: According to the interval between the radical surgery and the beginning of adjuvant imatinib, 222 patients were divided into three groups: group A (≤ 2 months, n = 41), group B (2-≤ 4 months, n = 113), and group C (4-≤ 6 months, n = 68). Univariate, multivariate, and survival analyses all showed that patients in group A had significantly more favorable RFS than those in group C but not group B, and patients taking adjuvant imatinib for over 12 months were also associated with longer RFS comparing to adjuvant imatinib of ≤ 12 months. When stratified by the duration of adjuvant imatinib, no significant differences were found in RFS among groups A, B, and C for adjuvant imatinib of ≤ 12 months. While for adjuvant imatinib of over 12 months, both groups A and B had significantly more favorable RFS than group C, and no significant difference in RFS was found between group A and B.

Conclusion: Delayed postoperative adjuvant imatinib for over 4 months in patients with high risk of recurrence of GIST may lead to worse RFS, and longer treatment with shorter delay has best results.

Keywords: Gastrointestinal stromal tumor; Imatinib; Recurrence-free survival.

PubMed Disclaimer

Conflict of interest statement

There was no conflict of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curves of recurrence-free survival for all patients in groups A, B, and C
Fig. 2
Fig. 2
Kaplan–Meier curves of recurrence-free survival for patients have different duration of adjuvant imatinib
Fig. 3
Fig. 3
Kaplan–Meier curves of recurrence-free survival for patients in groups A, B, and C (taking adjuvant imatinib for ≤ 12 months)
Fig. 4
Fig. 4
Kaplan–Meier curves of recurrence-free survival for patients in groups A, B, and C (taking adjuvant imatinib for > 12 months)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bengio RM, Riva ME, Moiraghi B, Lanari E, Milone J, Ventriglia V, Bullorsky E, Tezanos Pinto M, Murro H, Bianchini M, Larripa I (2011) Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. Leuk Lymphoma 52(9):1720–1726 - PubMed
    1. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CDM, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008a) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625 - PubMed
    1. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC (2008b) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632 - PubMed
    1. Cavnar MJ, Seier K, Curtin C, Balachandran VP, Coit DG, Yoon SS, Crago AM, Strong VE, Tap WD, Gonen M, Antonescu CR, Brennan MF, Singer S, DeMatteo RP (2019) Outcome of 1000 patients with gastrointestinal stromal tumor (GIST) treated by surgery in the pre and post-imatinib eras. Ann Surg 273(1):128 - PMC - PubMed
    1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1):51–58 - PMC - PubMed

MeSH terms

LinkOut - more resources